EGFR and glioblastoma: Glioblastoma researchers have also targeted growth factor receptors such as EGFR and PDGFR using small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and antibody drug conjugates [124], but these efforts have not yet translated into successful clinical trials.